Literature DB >> 31934297

Identifying TF-miRNA-mRNA regulatory modules in nitidine chloride treated HCC xenograft of nude mice.

Li Gao1, Dan-Dan Xiong1, Rong-Quan He2, Ze-Feng Lai3, Li-Min Liu3, Zhi-Guang Huang1, Xia Yang1, Hua-Yu Wu4, Li-Hua Yang2, Jie Ma2, Sheng-Hua Li5, Peng Lin6, Hong Yang6, Dian-Zhong Luo1, Gang Chen1, Yi-Wu Dang1.   

Abstract

Nitidine chloride (NC) has reported tumor suppressive activities for various human cancers, including hepatocellular carcinoma (HCC). Nevertheless, the pharmacological mechanism of NC on HCC has not previously been elucidated. SMMC7721 HCC cell lines, before and after the treatment of NC, were injected into nude mice for a subcutaneous tumor xenograft model. MiRNA and mRNA sequencing were performed for both control and treated xenograft tissues to further analyze differential expressed miRNAs (DEmiRNAs) and mRNAs (DEmRNAs). The ten most significant DEmiRNAs were selected for prediction of transcription factors (TFs) and target genes. We constructed an interconnected network composed of TFs the ten most significant DEmiRNAs, the 100 most significant DEmRNAs, and selected target genes from online programs. Hub genes chosen from a protein-to-protein interaction network of hub genes were validated by correlation analysis, expression analysis, and Kaplan-Meier survival analysis. The five most up-regulated miRNAs (hsa-miR-628-5p, hsa-miR-767-5p, hsa-miR-767-3p, hsa-miR-1257, and hsa-miR-33b-3p) and the five most down-regulated miRNAs (hsa-miR-378d, hsa-miR-136-5p, hsa-miR-451a, hsa-miR-144-5p, and hsa-miR-378b) were singled out from the DEmiRNAs. Functional annotations indicated that potential target genes of the top five up-regulated miRNAs were mainly clustered in molecular processes concerning epithelial-to-mesenchymal transition. Hub genes, such as ITGA6 and ITGB4, were validated as up-regulated in HCC; both IFIT2 and IFIT3 were revealed by Kaplan-Meier survival curves as good prognostic factors for HCC. In summary, the regulating axes of NC-DEmiRNAs-DEmRNAs and TFs-DEmiRNAs-DEmRNAs in HCC that were discovered in this study may shed light on the possible molecular mechanism of NC in HCC. AJTR
Copyright © 2019.

Entities:  

Keywords:  Nitidine chloride; hepatocellular carcinoma; microRNA; transcription factor; xenograft

Year:  2019        PMID: 31934297

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  5 in total

1.  SYNJ2 is a novel and potential biomarker for the prediction and treatment of cancers: from lung squamous cell carcinoma to pan-cancer.

Authors:  Wei Hou; Guo-Sheng Li; Li Gao; Hui-Ping Lu; Hua-Fu Zhou; Jin-Liang Kong; Gang Chen; Shuang Xia; Hong-Yu Wei
Journal:  BMC Med Genomics       Date:  2022-05-17       Impact factor: 3.622

2.  The circRNA-miRNA-mRNA regulatory network in systemic lupus erythematosus.

Authors:  Junhui Zhang; Yuan Liu; Guixiu Shi
Journal:  Clin Rheumatol       Date:  2020-06-12       Impact factor: 2.980

3.  The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues.

Authors:  Yu-Yan Pang; Jian-Di Li; Li Gao; Xia Yang; Yi-Wu Dang; Ze-Feng Lai; Li-Min Liu; Jie Yang; Hua-Yu Wu; Rong-Quan He; Zhi-Guang Huang; Dan-Dan Xiong; Li-Hua Yang; Lin Shi; Wei-Jia Mo; Deng Tang; Hui-Ping Lu; Gang Chen
Journal:  Cancer Med       Date:  2020-09-15       Impact factor: 4.452

4.  Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study.

Authors:  Xiaofang Zhang; Michelle M J Mens; Yasir J Abozaid; Daniel Bos; Sarwa Darwish Murad; Robert J de Knegt; M Arfan Ikram; Qiuwei Pan; Mohsen Ghanbari
Journal:  Aliment Pharmacol Ther       Date:  2020-11-27       Impact factor: 8.171

5.  Down-regulation of microRNA-125b-2-3p is a risk factor for a poor prognosis in hepatocellular carcinoma.

Authors:  He-Qing Huang; Gang Chen; Dan-Dan Xiong; Ze-Feng Lai; Li-Min Liu; Ye-Ying Fang; Jin-Hai Shen; Xiang-Yu Gan; Liu-Feng Liao; Yi-Wu Dang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.